Sight and insight – on the physiological role of nitric oxide in the visual system by Cudeiro Mazaira, Francisco Javier & Rivadulla, Casto
Trends in Neurosciences, Vol. 22, Issue 3, Pages 109-116 
Sight and insight – on the physiological role of nitric oxide in the 
visual system 
Javier Cudeiro, Casto Rivadulla 
Abstract 
Research in the fields of cellular communication and signal transduction in the brain has moved very rapidly in recent 
years. Nitric oxide (NO) is one of the latest discoveries in the arena of messenger molecules. Current evidence 
indicates that, in visual system, NO is produced in both postsynaptic and presynaptic structures and acts as a 
neurotransmitter, albeit of a rather unorthodox type. Under certain conditions it can switch roles to become either a 
neuronal ‘friend’ or ‘foe’. Nitric oxide is a gas that diffuses through all physiological barriers to act on neighbouring 
cells across an extensive volume on a specific time scale. It, therefore, has the opportunity to control the processing 
of vision from the lowest level of retinal transduction to the control of neuronal excitability in the visual cortex. 
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Visual processing starts in the retina. Here, the image of the world is broken down through visual 
filters (the receptive fields of individual neurones). In mammals this visual message then moves to an 
intermediate station in the thalamus, the dorsal lateral geniculate nucleus (dLGN). This is a laminar 
structure that receives the ganglion-cell axons in an organized manner depending on the eye from which 
the image originated, the cell type and other species-dependent characteristics. Finally, this information is 
relayed to the primary visual cortex (V1) from which connections are made with many other visual 
cortical and sub-cortical structures. At every level of this pathway, including the retina, passage of the 
visual message involves the activation of members of the family of excitatory-amino-acid receptors. 
However, besides these specific visual signals, there is also modulation of the visual message by a 
number of non-specific inputs (for example, dopaminergic, cholinergic and noradrenergic), which control 
the excitability of the neurones and gate the flow of information. Recently, a newly discovered 
neurotransmitter has emerged rather spectacularly that is involved in the processing of visual information 
– nitric oxide (NO). 
Nitric oxide: ubiquitous neurotransmitter or ‘saint–sinner’? 
Since NO was first recognized as a messenger molecule in the brain that mediates the increased cGMP 
levels that occur on activation of NMDA receptors1, major efforts have been made to understand the 
extent of its actions. Nitric oxide is a gas synthesized from l-arginine by the enzyme nitric-oxide synthase 
(NOS). At least three forms of the enzyme have been characterized: the constitutive endothelial and 
neuronal types are both Ca2+ dependent and the third is a Ca2+-independent inducible isoform, which is 
expressed only in the presence of cytokines. In this review, only data related to neuronal NOS (nNOS) 
will be considered. Available data from immunocytochemistry, in situ hybridization and NADPH-
diaphorase histochemistry have given a reasonably comprehensive picture of the anatomical localization 
of NO-generating cells and their processes throughout the CNS ( Ref. 2). The brain contains the highest 
level of NOS of any tissue so far examined and the broad distribution of the enzyme suggests that NO 
could be involved in many aspects of CNS function 1. 
However, NO might be a ‘double-edged sword’. In some studies it has been considered to be 
potentially neurotoxic3. Indeed, in the presence of factors such as oxidative stress, generation of reactive 
oxygen intermediates and deficient antioxidant systems, NO can induce neural death4. The majority of 
evidence indicates that the participation of NO in neurodegenerative phenomena occurs through a non-
enzymatic reaction with the superoxide anion (O2
·−) to form peroxynitrite (ONOO−) (see Table 1), which 
is a highly reactive molecule and a potent oxidizing agent5. Other mechanisms of NO toxicity, by DNA 
damage6 or glutathione depletion7 have also been postulated. However, these pathological effects remain, 
to some extent, controversial and confusing. Some laboratories using brain-slice or primary-tissue-culture 
models of glutamate neurotoxicity have reported that NO is also involved in these pathologies8 and 9, while 
others, employing similar methods, have shown no obvious role10 and 11. Furthermore, there is also much 
evidence to suggest that NO might be neuroprotective12, 13 and 14. Differences between the effects of NO 
have been attributed, at least in part, to different redox-related species of the NO group and their disparate 
chemical activities. Neurodestruction has been attributed to peroxynitrite alone and not to NO− (the 
reduced form), and the neuroprotective properties of NO have been attributed to NO+ (the oxidized form), 
as this species downregulates NMDA-receptor activity by reaction with thiol group(s) in the redox 
modulatory site of the receptor15, 16 and 17 (Fig. 1). 
Table 1. Products and targets of neuronal nitric oxide synthasea 
Nitric oxide-related species Principal biological target-reactants 
  
N2O Metals, hydrophobic pockets 
NH2OH Oxidants 
NO− (MNO; SNO) Thiols, metals, oxygen 
NO· (MNO; SNO) Thiols, metals, superoxide, oxygen 
NOx–SNO–MNO (NO
+) Thiols 







a All of the above nitric oxide (NO)-related species have been identified from purified preparations of neuronal nitric oxide synthase 
(NOS)94. The cellular availability of substrates and cofactors appears to influence the oxidation state of the NOS product. Nitrous 
oxide (N2O) and hydroxylamine (NH2OH) are end-reduction products, while nitrite–nitrate (NO2
−–NO3
−) are end-oxidation 
products. The remaining compounds have different biological actions and potential toxicities that reflect their chemistry in different 
redox milieu95, 96 and 97. Note that different SNO and MNO species might function as NO·, NO+, or NO− donors. Adapted, with 




Fig. 1. Presynaptic and postsynaptic locations of nitric-oxide synthase (NOS) and the probable routes of action of nitric 
oxide (NO).(A) Postsynaptic location of NOS, showing possible presynaptic actions (red arrows). Calcium signal from glutamate-
mediated activation of NMDA receptors or voltage-dependent Ca2+ channels (VDCCs) binds calmodulin (CaM) and activates NOS, 
producing NO and citrulline from l-arginine (reviewed in Ref. 1). The free diffusion of NO suggests that this presynaptic activity 
need not necessarily be restricted to the presynaptic boutons directly involved with this postsynaptic element. (B) Presynaptic 
location of NOS, showing possible postsynaptic actions. Note the direct actions on the NMDA receptor, which is expanded in the 
inset box and shows the different modulatory sites. Neurotransmitter (NT) release is triggered by the arrival of an action potential in 
the presynaptic terminal by the opening of VDCCs. The resulting elevation in the internal Ca2+ concentration, is the signal that 
causes NO production. This has been shown to occur in the dorsal lateral geniculate nucleus of the cat 18, 19 and 20, where NOS is co-
localized with ACh within the axons arising from the brainstem 21. Again, diffusion of NO can induce actions on sites that are 
remote from the synapse illustrated here. Therefore, the possibility of combined presynaptic and postsynaptic activities from either 
NOS location cannot be excluded. Abbreviations: Glu, glutamate; SNAP25, 25 kDa synaptosomal-associated protein. 
 
To complete this brief overview, and yet add another level of complexity, it is important to make clear 
that, although the best recognized effectors for NO are adenylate cyclase and cGMP, they are not the only 
ones and many NO-mediated effects are cGMP independent. These pathways have typically been 
grouped under the broad heading of redox-related NO signals and can be well-regulated post-translational 
modifications that are part of cellular control mechanisms22. In neurones several enzymes, G proteins, 




 Thus, in brief, NO seems to be an almost-ubiquitous messenger substance in the CNS that can, under 
certain conditions (such as its excessive production or the absence of regulatory control mechanisms), be 
toxic to cells, while possibly also being capable of acting as a neuroprotectant. However, under normal, 
physiological conditions NO seems to act as a neurotransmitter, albeit of a novel and unusual type. 
Within the more restricted field of sensory neurobiology there currently exists a lesser but no less 
significant interest in NO. Although NO has been demonstrated at all levels of the sensory CNS and 
across many modalities, there is a large amount of evidence for its presence and action in the visual 
system (see Fig. 2). Data exist that show NO has a role in the visual system from retina to cerebral cortex 
and it seems appropriate that a review of these studies is made. 
Table 2. Neuronal targets of nitric oxide-related speciesa 
Targets Effect Refs 
   
Guanylate cyclase LTP, modulation of visual processing at the level of primary visual cortex  
NMDA receptor Neuroprotection, facilitation of NMDA-mediated responses in dLGN  
SNAP25 Synaptic plasticity and transmission 98 
Syntaxin 1a Synaptic vesicle docking–fusion 99 
n-sec1 Synaptic vesicle docking–fusion 99 
Neurogranin LTP, neurotransmitter release 100 
H+-ATPase Vesicular glutamate uptake 101 
Cyclic nucleotide-gated 
channel 
Olfactory transduction, visual transduction, modulation of retinal ganglion-
cell activity 
102 
Ca2+ channel (rods) Retinal photoreceptor function  
Na+/K+-ATPase Ion homeostasis 103 
?VAMP  99 
ADP ribosyltransferase LTP, modulation of visual transduction 104 




Fig. 2. Distribution of nitric-oxide synthase (NOS) containing cells and NOS positive fibres in the visual system. Summary of 
the three primary levels of the mammalian visual system. (A) Nitric oxide (NO) is produced in photoreceptors (P), horizontal cells 
(H), amacrine cells (A), Müller cells (M) and ganglion cells (G) (red) 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 and 36. In the retina it regulates 
phototransduction 37 and 38; modulates photoreceptor output 37, 39, 40, 41 and 42, bipolar cells 38 and horizontal cells 43, 44, 45, 46, 47, 48 and 49; 
controls ganglion-cell excitability 50 and modulates the electroretinogram 38 and 51. The widespread distribution of NOS-positive cells 
in these areas gives rise to possible modulation of retinal processes at all three levels by NO. The time course of effects at each level 
is likely to be similar because the half-life of NO in vitro has been estimated to be around 6 s ( Ref. 52) (although in vivo it could be 
much longer 53). These effects on retinal processing include: (1) regulation of phototransduction (altering levels of cGMP and by 
ADP ribosylation); (2) modulation of output at photoreceptor synapses (by altering Ca2+ currents); (3) activation of ON-bipolar cells 
(by acting on its NO-sensitive GC); (4) decreasing the lateral spread of light responses (by decreasing electrical coupling and 
responsiveness to glutamate in horizontal cells); and (5) controlling ganglion-cell excitability and thereby the retinal output (by 
acting on cGMP-gated cation channels). (B) In the cat, monkey and human dorsal lateral geniculate nucleus (dLGN) there are no 
NOS-positive cells 21, 54, 55, 56 and 57, but they are found in small mammals such as rats and tree shrews 58, 59, 60, 61 and 62. Massive 
projection of NOS-positive terminals from the brainstem are shown in red 21. In the dLGN, nitric oxide modulates NMDA-receptor 
activation, the gating of visual transmission 18, 19 and 20, the control of oscillatory activity 63 and has an important role in development 
in this region 64, 65, 66, 67, 68, 69, 70 and 71. (C) Scattered NOS-producing neurones are found in all layers of the cortex (red), many in the 
white matter (WM) 29, 55, 57, 58, 62, 72, 73 and 74. Here NO modulates visual responses via cGMP ( Ref. 75) and is involved in the regulation 
of presynaptic neurotransmitter release 76. 
The retina 
In a general scheme of vertebrate retinal physiology, visual excitation in photoreceptors is mediated 
by the light-triggered hydrolysis of intracellular cGMP and is transmitted via bipolar cells to the output, 
ganglion-cell layer of the retina. The visual signal is laterally modulated by two major classes of 
neurones: horizontal cells located in the outer plexiform layer and amacrine cells located in the inner 
retina. Such modulation is carried out via chemical synapses using a number of different 
neurotransmitters, and also by electrical coupling77. There is now much evidence that demonstrates that 
NO has a role in the physiological regulation of diverse processes within the retina, from the transduction 
to the gating of the output signal. These include: 
Localization of nitric-oxide synthesis 
Nitric-oxide synthase has been reported to have NADPH-diaphorase (NADPH-d) activity78 and 79 and 
both histochemical detection of NADPH-d activity and immunoreactivity to antibodies raised against 
NOS are used extensively as methods for identifying nNOS. These methods have revealed that horizontal, 
amacrine and ganglion cells of different mammals78, 23, 24, 25, 26, 27 and 28 and non-mammals29 and 30 contain 
nNOS. Moreover, human retinal tissues have been found to express mRNA for constitutive and inducible 
NOS (Ref. 31). The presence of nNOS activity in photoreceptors has been a matter of controversy. 
Several studies using immunocytochemical and NADPH-d histochemical staining failed to localize nNOS 
activity78, 80 and 81. Nevertheless, other studies, including the most recent, claim that nNOS activity to be 
present in the inner and outer segments of photoreceptor rods25, 26, 32, 33, 34 and 35. Furthermore, using 
NADPH-d histochemistry to study the cone-dominated retina of the tree shrew it has been possible to 
reveal several patterns of activity in the cellular subcompartments of the spectral classes of cones, which 
suggests that NO may be differentially involved in the functioning of different classes of 
photoreceptors36. Interestingly, there is also evidence that NOS is found in Müller cells of both fish and 
amphibian species, suggesting yet another route by which NO can modulate retinal function29. 
NO affects the metabolism of cGMP in a variety of cells 
(1) Available data show that NO is functionally coupled to a soluble guanylate cyclase and might be 
able to increase cGMP levels in rod photoreceptors thereby increasing the cGMP-gated conductances37, 
which affect both response amplitude and response kinetics82. Nitric oxide has also been shown to 
modulate Ca2+ channels and transmission of the photoresponse to second-order cells37, and to increase 
adenosine diphosphate (ADP) ribosylation of a variety of proteins such as transducin, G proteins and 
other, as yet unidentified, proteins in the outer segment of photoreceptor rods39, 40 and 41. These alterations 
of cellular proteins could be a mechanism by which NO modifies the operational mode of enzymes in the 
visual transduction cascade38. Nitric oxide can also modulate Ca2+ and cyclic-nucleotide-gated channels 
in both rod and cone photoreceptors, which control exocytosis at cone synapses, thereby altering synaptic 
efficacy42 and 83. 
(2) Work carried out in fish has shown that NO donors, NOS inhibitors and NO-related substances 
modify electrical coupling in horizontal cells in such a way that the presence of cGMP, l-arginine or the 
NO donor, sodium nitroprusside, decreases electrical and dye-tracer coupling between the cells43 and 44. 
This modulation of the gap-junctional conductance seems to be produced by activating the cGMP-
dependent protein kinase G (PKG) pathway45. Nitric oxide might also modify horizontal-cell activity by 
actions on chemical synapses. For example, NO reduces the responsiveness of glutamate receptors on 
retinal horizontal cells taken from the hybrid bass retina46. Interestingly, while dopamine is known to 
modify electrical coupling in horizontal cells43 and 47 and NO has been shown to modulate dopamine 
release in the retina48, these actions seem separate, because the action on dopamine release seem to affect 
only K+-mediated release and not basal release49. In summary, NO acts to downregulate horizontal-cell 
activity, which can alter apparent receptive-field size and thus influence the lateral spread of light-
responses in the retina, while at the same time protecting horizontal cells from glutamate excitotoxicity. 
(3) Both bipolar and ganglion cells are susceptible to the influence of NO. Guanylate cyclase (GC) of 
ON-bipolar cells is of the NO-sensitive type and increased levels of cGMP have been reported after the 
application of NO donors38. More recently, a cGMP-gated non-selective cation channel, whose 
conductance is increased by NO donors, has been found in ganglion cells50. Thus, because nNOS activity 
is present within the ganglion-cell layer, it is plausible that a NO–cGMP system exists there that 
modulates retinal output. 
All the studies mentioned so far have been carried out using in vitro preparations (mainly dissociated 
cells). Without doubt these have been useful and have made it possible to investigate problems that are 
otherwise unexaminable by current in vivo techniques. However, the disruption of the functional anatomy 
of the retina can clearly alter response properties of this complex system, which makes the use of 
different and complementary experimental approaches necessary. Recent studies that recorded the 
electroretinogram (ERG) in the intact cat eye 38 or both ERG and compound action potentials from the 
optic nerve in the intact rabbit retina 51 during application of NO-related compounds suggest that NO 
contributes physiologically to retinal processing. 
The thalamus 
In mammals, the dLGN plays a pivotal role in the transmission of visual information to the cerebral 
cortex. Unlike the retina, this is a site where both processing and gating of information takes place – 
thalamic transmission can be modulated by a number of inputs that arise from the brainstem84 and are 
dependent upon the behavioural state of the organism. Moreover, processing and gating in the dLGN are 
also functions that are intimately associated with, and regulated by, neural functioning in the visual 
cortex, by virtue of the large descending corticofugal input. 
Neuronal NOS activity has been found in the thalamus of variety of species. For example, NADPH-d-
positive cells have been seen in the ventral division of the LGN in rats and tree shrews58 and 59, and 
NADPH-d reactivity and GABA (Ref. 60) are co-localized in a subpopulation of local inhibitory 
interneurones in the dLGN of the rat61. Furthermore, NOS activity has also been detected in the visual 
thalamus by immunocytochemistry62. Interestingly, in higher mammals, such as the cat, the monkey and 
human beings, the dLGN are completely devoid of nNOS-containing neurones, although a dense network 
of axons and terminals are labelled (Fig. 2B; 54, 55, 56 and 57). Recent evidence has shown that the cat 
dLGN contains a unique distribution of nNOS, found exclusively within the cholinergic fibres that 
originate in the parabrachium21. This represents a novel co-localization of neurotransmitters and shows an 
exclusively presynaptic location for nNOS. It has been demonstrated in vivo that NO can potently 
enhance those visual responses that are due specifically and selectively to NMDA-receptor-mediated 
excitation in this region 18, 19 and 20 ( Fig. 3B). Such an action is likely to be postsynaptic in origin and does 
not involve cGMP ( 19 and 20). This in vivo discovery is puzzling because it is contrary to what has been 
reported by several groups using in vitro models, where NO inhibits NMDA-receptor channels by an 
action on the redox modulatory site 15. One possible explanation is that because, as already outlined, NO 
can exist in distinct oxidation–reduction states that have different biological actions 15, 16 and 17, it can have 
opposite effects depending on the local redox milieu. However, there are also reports that NO affects 
NMDA-mediated activity independently of cGMP and the NMDA-associated redox site 85. It has even 
been suggested that NO might modulate NMDA currents by stimulating the release of glycine, the co-
factor for NMDA activation 86 (see Fig. 1). Other experiments in cat dLGN in vitro showed that 
application of NO to thalamocortical neurones had a direct postsynaptic depolarizing effect that was 
associated with a decrease in input resistance. These small depolarizations appeared to act via the cGMP 
second-messenger system and relate to the control of oscillatory firing patterns 63 ( Fig. 3C). This cGMP-
mediated action of NO might be involved in the control of different patterns of electrogenic activity 
during various states of the sleep–wake cycle. However, the demonstrable effects of the block of nNOS in 
vivo do not operate via the cGMP cascade, as the soluble cGMP analogue, 8-bromo-cGMP, has been 





Fig. 3. Summary of the actions of the nitric-oxide system in the feline dorsal lateral geniculate nucleus (dLGN).(A) Control 
visual responses to small spot of light centred over the receptive field centre (centre). Application of the nitric-oxide (NO) donor, s-
nitroso-N-acetyl-(d,l)-penicillamine (SNAP), increases responsiveness (right). Application of l-NOArg, a nitric-oxide synthase 
(NOS) inhibitor, suppresses visual responses (left). Adapted, with permission, from Ref. 20. (B) Histogram showing that application 
of the NOS antagonist, l-NOArg, depresses responses to applied NMDA in a highly selective fashion, compared to similar tests with 
the other drugs KAIN (kainic acid), QUIS (quisqualic acid), AMPA and ACh. Reproduced, with permission, from Ref. 19.(C) 
Intracellular recordings of a feline geniculate cell in vitro. Example of a neurone that spontaneously generates rhythmic Ca2+-
mediated burst activity. Generation of NO through SIN 1 reversibly inhibits this activity. Indicated segments are expanded for 
details. Adapted, with permission, from Ref. 63. 
In summary, in the visual thalamus it can be hypothesized that NO can act wherever brainstem 
parabrachial terminals arborize, with production regulated by activity levels in these fibres in a Ca2+-
dependent manner. While the basal release of NO can contribute to control of oscillatory activity, which 
is dependent on the behavioural status of an organism, it can also facilitate visual transmission from the 
retina through the dLGN to the cortex, particularly when such transmission invokes the activation of 
voltage-dependent NMDA receptors. Furthermore, NO might affect simultaneously the functional status 
of a relatively large neuronal population by local diffusion. Indeed, a theoretical model has predicted that 
the sphere of influence of a single point source of NO has a diameter of about 200 μm, corresponding to a 
volume in the brain that encloses up to two million synapses1.  
A role for NO in the development of subcortical structures 
A role for NO in development has been described in different species. In rats, the superior colliculus is 
a major target for retinal axons and the refinement of retinocollicular connections takes place during the 
first few postnatal weeks. Given that nNOS is expressed in the retinorecipient layers of the rat superior 
colliculus during this period, it has been suggested that NO has a role in synaptic refinement64 and 65. 
Similarly, in the chick, the superficial layers of the optic tectum are the main sites for termination of 
retinal axons. Prior to the innervation by retinal axons, NADPH-d-stained cells are found only in deep 
layers. When axons innervate this area, NADPH-d-positive cells appear in the superficial layers, 
progressively increasing in number until the peak period for remodelling of retinal connections , which 
coincides with the loss of several transient projections, occurs. This loss is reduced if NO synthesis is 
inhibited66. Although the exact mechanism by which NO mediates this effect is not clearly understood, it 
has been suggested that coordinated activity in the major inputs, NMDA-receptor activation and NO 
production could each have a key role66. Interestingly, in the tadpole explanted retina, application of NO 
donors results in the collapse of active growth cones of ganglion-cell axons; such a mechanism could 
explain the termination of axonal growth at the tectal level during development67. 
Similar results have been found in the dLGN of the ferret and the cat where NOS is transiently 
expressed during the period in which projections from the retina are refined68 and 69. In the ferret dLGN, 
retinal information is segregated into ON–OFF sublaminae, a process that requires NMDA-receptor 
activation, and application of a NOS inhibitor resulted in an overall pattern of sublamination that was 
clearly reduced when compared with normal animals70. In the developing kitten (by contrast with the 
adult cat), NADPH-d staining of dLGN cells suggested that NO might act in a retrograde fashion and 
perhaps have a role in the maintenance of associative processes that underlie activity-dependent 
refinement of retinogeniculate connections69. Further indirect results on the putative role of NO on 
development and plasticity have also been obtained in cats. After monocular lid suturing as kittens, adult 
cats showed an abnormal presence of NADPH-d-positive cells within the dLGN, which was not seen in 
normally reared controls, clearly indicating that NOS activity can be induced (or perhaps retained) by 
visual deprivation71. 
Visual cortex 
In the cerebral cortex, NO production could arise from several possible sources (see Fig. 2C): 
extrinsically from cholinergic fibres that originate in the forebrain87; from cortical blood vessels capable 
of NO production from endothelial cells of blood-vessel walls88 and intrinsically from cells within the 
cortex that contain nNOS (a subset of the non-spiny cortical cells58 and 78). Neurones containing nNOS 
were observed scattered throughout all cortical regions (Fig. 4) from layers II to VI and in the subcortical 
white matter in several species including the rat58 and 62, cat72, monkey55 and 73 and human beings57 and 74. 
Such a diversity of production sites suggests a complex role or roles for NO in cortical visual processing. 
Examples to support this include: (1) in primate, the distribution of NADPH-d staining is closely aligned 
with that of cytochrome oxidase and shows a similar laminar and spatial distribution73. This could suggest 
a role for NOS that is associated with parvocellular, wavelength selective neurones. (2) Recent evidence 
has shown that NO might be involved in the NMDA-mediated release of noradrenaline and glutamate 
from rat cortical synaptosomes, thereby suggesting that NO has both direct actions in the visual cortex 
and actions on modulatory processes76. Investigations centred specifically on the visual cortex of the 
anaesthetized cat have shown that application of compounds that manipulate the NO system alter 
responsiveness of a substantial proportion of neurones to visual stimuli, either reducing or augmenting 
visual responses. This regulation of cortical visual processing seems to be mediated via the cGMP 
second-messenger system75 (Fig. 5) and suggests the existence of both upregulation and downregulation 
of cellular firing in separate subpopulations of cortical cells, which could be related to the level of 











Fig. 4. NADPH-diaphorase staining in macaque primary visual cortex. Photomicrographs of NADPH diaphorase-positive 
neurones and fibres in the visual cortex (area V1) of a macaque monkey stained according to the protocol of Hope and Vincent89. 
Moderately and darkly stained neurones are localized mainly in layers II, the upper half of layer III, the lower third of layer VI, and 
in the white matter. (A) Low-power photomicrograph from layer I to the white matter (WM). The black arrow indicates a strongly 
stained nonpyramidal cell that is also shown at higher magnification in (B) and (C). (B) Photomicrograph from layers I to III 
showing numerous lightly or moderately stained neurones (red arrows) and the plexus of horizontally oriented fibres (f) located in 
the upper half of layer I. (C) High-power photomicrograph of the darkly stained cell (black arrow) also indicated in (A) and (B). 
Note the dense network of fibres running in all directions. The red arrow indicates a lightly labeled neurone. Scale bar, 172 μm in 
(A), 75 μm in (B) and 35 μm in (C). The photomicrographs were provided by Dr Javier DeFelipe, Cajal Institute, Spain. Cortical 
neurones synthesizing nitric oxide are currently visualized with NADPH-diaphorase histochemistry or immunocytochemistry for 
neuronal nitric-oxide synthase (nNOS). These neurones mainly represent a subpopulation of GABAergic non-pyramidal cells 
(interneurones) that contain the peptides somatostatin and neuropeptide Y, and frequently contain the Ca2+-binding protein 
calbindin, but not parvalbumin and calretinin. These GABAergic cells also show little or no co-localization with the peptides 






Fig. 5. Peri-stimulus time histograms illustrating the range of activities of nitric oxide (NO) and related compounds in cat 
visual cortex.(A) Control visual response of a directionally selective complex cell (centre). Application of DEA-NO, a NO donor, 
increases the response to the stimulus (right). Application of l-NOArg, a NOS inhibitor, decreases the same response (left). (B) 
Control visual responses of a non-directionally selective complex cell (centre). DEA-NO causes almost complete response 
suppression (right). l-NOArg application greatly increases responses in both directions equally (left). Drugs were applied by 
iontophoresis and responses averaged over a number of stimulus trials. Cells were driven monocularly through the dominant eye and 
the stimulus orientation selected from a quantitatively derived orientation tuning curve. Adapted, with permission, from Ref. 75. 
Interestingly, in contrast to studies mentioned above that show a role for NO in the development of 
subcortical visual structures, there is no evidence to date to suggest a similar developmental role for NO 
in the visual cortex91 and 92, even though NOS distribution in visual cortex can be altered by manipulation 
of visual inputs55. 
Concluding remarks 
One of the most intriguing features of NO, considering the simplicity of the molecule, is that it is 
involved in so many different regulatory functions and has many other effects. At low concentrations, it 
can work as a neuromodulator or a retrograde messenger in the CNS; at relatively high concentrations it 
can be toxic. It is tempting to speculate that NO could have multiple roles in separate regions and circuits, 
each role related to local physiological functions and not necessarily part of the more general role that NO 
has in neurotoxicity or neuroprotection. These represent alterations of normal homeostatic function of the 
CNS and its regulatory mechanisms. It is important to note the significance of in vivo studies and to 
understand the need for studies of the physiology of whole systems. 
Nitric oxide, the gas, the common air pollutant, the suspected carcinogen and the destroyer of ozone 
could be the archetypal example used to illustrate the concept of ‘parasynaptic’ information transmission 
in the brain, a domain of versatility and plasticity, as formulated by Schmitt93 ‘…new ways of 
conceptualization of information–transactional chemical processes as applied to basic concepts of 
neurobiology’, in this case to the concept of vision. 
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